TNXP Valuation

Tonix Pharmaceuticals Holding Corp

Add to Watchlist

Advanced Chart

46.490

-0.43(-0.916%)1D

Overview
Forecast
Valuation
Earnings

TNXP Relative Valuation

TNXP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TNXP is overvalued; if below, it's undervalued.

Historical Valuation

Tonix Pharmaceuticals Holding Corp (TNXP) is now in the Fair zone, suggesting that its current forward PS ratio of 12.65 is considered Fairly compared with the five-year average of -1.36. The fair price of Tonix Pharmaceuticals Holding Corp (TNXP) is between 36.44 to 59.51 according to relative valuation methord.

Relative Value

Fair Zone

36.44-59.51

Current Price：46.49

Fair

-3.88

Trailing

Forward

0.00

EV/EBITDA

Tonix Pharmaceuticals Holding Corp. (TNXP) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -1.99. The thresholds are as follows: Strongly Undervalued below -17.45, Undervalued between -17.45 and -9.72, Fairly Valued between 5.74 and -9.72, Overvalued between 5.74 and 13.48, and Strongly Overvalued above 13.48. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-2.75

EV/EBIT

Tonix Pharmaceuticals Holding Corp. (TNXP) has a current EV/EBIT of -2.75. The 5-year average EV/EBIT is -0.37. The thresholds are as follows: Strongly Undervalued below -2.74, Undervalued between -2.74 and -1.55, Fairly Valued between 0.82 and -1.55, Overvalued between 0.82 and 2.01, and Strongly Overvalued above 2.01. The current Forward EV/EBIT of -2.75 falls within the Strongly Undervalued range.

12.65

Tonix Pharmaceuticals Holding Corp. (TNXP) has a current PS of 12.65. The 5-year average PS is 1.55. The thresholds are as follows: Strongly Undervalued below -3.87, Undervalued between -3.87 and -1.16, Fairly Valued between 4.25 and -1.16, Overvalued between 4.25 and 6.96, and Strongly Overvalued above 6.96. The current Forward PS of 12.65 falls within the Strongly Overvalued range.

0.00

P/OCF

Tonix Pharmaceuticals Holding Corp. (TNXP) has a current P/OCF of 0.00. The 5-year average P/OCF is -2.81. The thresholds are as follows: Strongly Undervalued below -27.29, Undervalued between -27.29 and -15.05, Fairly Valued between 9.44 and -15.05, Overvalued between 9.44 and 21.68, and Strongly Overvalued above 21.68. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Tonix Pharmaceuticals Holding Corp. (TNXP) has a current P/FCF of 0.00. The 5-year average P/FCF is -1.70. The thresholds are as follows: Strongly Undervalued below -23.50, Undervalued between -23.50 and -12.60, Fairly Valued between 9.21 and -12.60, Overvalued between 9.21 and 20.11, and Strongly Overvalued above 20.11. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Tonix Pharmaceuticals Holding Corp (TNXP) has a current Price-to-Book (P/B) ratio of 1.77. Compared to its 3-year average P/B ratio of 0.29 , the current P/B ratio is approximately 503.31% higher. Relative to its 5-year average P/B ratio of 0.72, the current P/B ratio is about 147.53% higher. Tonix Pharmaceuticals Holding Corp (TNXP) has a Forward Free Cash Flow (FCF) yield of approximately -14.74%. Compared to its 3-year average FCF yield of -534.63%, the current FCF yield is approximately -97.24% lower. Relative to its 5-year average FCF yield of -351.69% , the current FCF yield is about -95.81% lower.

1.77

P/B

Median3y

0.29

Median5y

0.72

-14.74

FCF Yield

Median3y

-534.63

Median5y

-351.69

Competitors Valuation Multiple

The average P/S ratio for TNXP's competitors is 39.63, providing a benchmark for relative valuation. Tonix Pharmaceuticals Holding Corp Corp (TNXP) exhibits a P/S ratio of 12.65, which is -68.09% above the industry average. Given its robust revenue growth of -2.14%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

TNXP.O

Tonix Pharmaceuticals Holding Corp

Esperion Therapeutics Inc

Atea Pharmaceuticals Inc

Loss

268.23M

SCPH.O

scPharmaceuticals Inc

2.39

99.17%

246.77M

Performance Decomposition

Market capitalization of TNXP increased by 103.01% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -0.41 to -0.78.

The secondary factor is the Margin Expansion, contributed 15.11%to the performance.

Overall, the performance of TNXP in the past 1 year is driven by P/E Change. Which is more unsustainable.

-2.14%

2.48M → 2.43M

Revenue Growth

15.11%

-601.89 → -692.84

Margin Expansion

90.04%

-0.41 → -0.78

P/E Change

103.01%